Curia completes the acquisition of Integrity Bio



ALBANY, NY – (COMMERCIAL THREAD) – Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced that it has completed the transaction to acquire Integrity Bio, Inc., a privately-held formulating and filling organization whose the headquarters are in Camarillo, California. The addition of Integrity Bio’s two California sites enhances Curia’s drug formulation development capabilities and expands its fill-finish network, which also includes Curia’s three centers of excellence in Albuquerque, New Mexico; Burlington, Massachusetts and Glasgow, Scotland.

“We are delighted to welcome our Integrity Bio colleagues to Curia, bringing their in-depth scientific expertise and dedication to improving the lives of patients,” said Curia President and CEO John Ratliff. “Our investment in this acquisition expands our global footprint and demonstrates our commitment to deepen our scientific know-how, particularly in organic products. Together, we can provide our customers with end-to-end solutions, from research and development to commercial manufacturing. Our compelling combination takes our clients from curiosity to healing. ”

Integrity Bio will migrate to the Curia brand in the future. It will continue to use its name for an interim period, adding “Now part of the Curia” to its logo. Its Managing Director, Michael Reilly, will be part of Curia’s research and development leadership team led by Christopher Conway, President, R&D.

About the Curia

Curia, formerly AMRI, is a leading contract research, development and manufacturing organization that provides products and services ranging from R&D to commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,400 employees at 23 locations in the United States, Europe and Asia help clients move from curiosity to healing. Learn more about



Leave A Reply